Table 2 Clinical data according to TET2... | American Society of Hematology

Table 2

Clinical data according to TET2 status in AITL and PTCL-NOS patients

n	TET2 mutation		TET2 wild-type		P
n	62		82		P
Sex
Male	38	61%	43	52%	.18*
Female	24	39%	39	48%	.18*
Median age, y	67		65		.3†
Stage
1	0	0%	4	5%	.028‡
2	0	0%	3	4%
3	11	21%	17	23%
4	42	79%	49	67%
Median no. of extranodal localizations	2		1		.056†
Lactate dehydrogenase
Elevated	41	76%	46	65%	.24*
Normal	13	24%	25	35%	.24*
Hemoglobin
≥ 10 g/dL	35	74%	33	60%	.14*
< 10 g/dL	12	26%	22	40%	.14*
Platelet count
≥ 150 000/mm³	34	72%	48	89%	.04*
< 150 000/mm³	13	28%	6	11%	.04*
Direct Coombs test
Positive	14	52%	13	43%	.6*
Negative	13	48%	17	57%	.6*
Hypergammaglobulinemia
Yes	11	32%	12	33%	> .999*
No	23	68%	24	67%	> .999*
B symptoms
Yes	40	78%	38	58%	.028*
No	11	22%	27	42%	.028*
Performance status
0-1	22	44%	41	62%	.06*
2-4	28	56%	25	38%	.06*
International Prognosis Index score
0	0	0%	4	6%	.0062†
1	2	4%	4	6%
2	8	16%	11	16%
3	10	20%	22	33%
4	19	37%	23	34%
5	12	24%	3	4%
Prognosis Model for PTCL¹⁸
0	2	5%	4	9%	.0045†
1	3	7%	11	24%
2	9	21%	13	29%
3	18	43%	13	29%
4	10	24%	4	9%
Treatment
Anthracycline-based regimen	37	69%	40	58%	.5*
Anthracycline-based regimen and frontline transplantation	2	4%	8	12%
Other combination of chemotherapy	7	13%	8	12%
Single-agent chemotherapy	5	9%	7	10%
Palliative treatment	3	6%	6	9%
5-y overall survival	28%		31%		.11§
5-y PFS	10%		21%		.047§

n	TET2 mutation		TET2 wild-type		P
n	62		82		P
Sex
Male	38	61%	43	52%	.18*
Female	24	39%	39	48%	.18*
Median age, y	67		65		.3†
Stage
1	0	0%	4	5%	.028‡
2	0	0%	3	4%
3	11	21%	17	23%
4	42	79%	49	67%
Median no. of extranodal localizations	2		1		.056†
Lactate dehydrogenase
Elevated	41	76%	46	65%	.24*
Normal	13	24%	25	35%	.24*
Hemoglobin
≥ 10 g/dL	35	74%	33	60%	.14*
< 10 g/dL	12	26%	22	40%	.14*
Platelet count
≥ 150 000/mm³	34	72%	48	89%	.04*
< 150 000/mm³	13	28%	6	11%	.04*
Direct Coombs test
Positive	14	52%	13	43%	.6*
Negative	13	48%	17	57%	.6*
Hypergammaglobulinemia
Yes	11	32%	12	33%	> .999*
No	23	68%	24	67%	> .999*
B symptoms
Yes	40	78%	38	58%	.028*
No	11	22%	27	42%	.028*
Performance status
0-1	22	44%	41	62%	.06*
2-4	28	56%	25	38%	.06*
International Prognosis Index score
0	0	0%	4	6%	.0062†
1	2	4%	4	6%
2	8	16%	11	16%
3	10	20%	22	33%
4	19	37%	23	34%
5	12	24%	3	4%
Prognosis Model for PTCL¹⁸
0	2	5%	4	9%	.0045†
1	3	7%	11	24%
2	9	21%	13	29%
3	18	43%	13	29%
4	10	24%	4	9%
Treatment
Anthracycline-based regimen	37	69%	40	58%	.5*
Anthracycline-based regimen and frontline transplantation	2	4%	8	12%
Other combination of chemotherapy	7	13%	8	12%
Single-agent chemotherapy	5	9%	7	10%
Palliative treatment	3	6%	6	9%
5-y overall survival	28%		31%		.11§
5-y PFS	10%		21%		.047§

Fisher exact test.

Wilcoxon sum-rank test.

Cochran Armitage test.

Log-rank test.